Table 1.

Endpoints and adverse events

	Ocrelizumab (n = 2)		Placebo (n = 1)
Antibody	LGI1	NMDAR	NMDAR
Confirmed clinical worsening (primary endpoint)	No	No	Yes
Time to clinical worsening (secondary endpoint)	–	–	12 weeks
mRS at first visit	3	4	2
mRS at last visit	3	1	1
Continued seizures during study	Yes	Yes	No
Adverse events
Any adverse event	Rash	Rash Liver enzyme increase	Rash
Infusion reactions	No	No	No
Serious adverse events (SAE)	Arm fracture	Hospitalization for seizures (due to medication nonadherence)	None
Serious infections	No	No	No

LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-d-aspartate receptor